| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Collaboration arrangement revenue | NaN | 53,737 | NaN | NaN |
| Research and development | 3,218 | 3,316 | 3,555 | 5,161 |
| General and administrative | 4,504 | 4,543 | 4,022 | 4,010 |
| Total operating expenses | 7,722 | 7,859 | 7,577 | 9,171 |
| Loss from operations | -7,722 | 45,878 | -7,577 | -9,171 |
| Change in fair value of convertible notes | NaN | 0* | 0 | 0 |
| Gain on sale of asset | NaN | 11,737* | NaN | NaN |
| Other income | 113 | 115 | 188 | -318 |
| Total other income | 113 | 11,852 | 188 | -318 |
| Income (loss) before provision for income taxes and loss from equity method investment | NaN | 57,730 | -7,389 | -9,489 |
| Provision for income taxes | NaN | 0* | NaN | 0 |
| Loss from equity method investment | NaN | 0* | 0 | 0 |
| Net loss and comprehensive loss | -7,609 | 57,730 | -7,389 | -9,489 |
| Basic EPS | -0.54 | 4.594 | -0.6 | -0.78 |
| Diluted EPS | -0.54 | 4.573 | -0.6 | -0.78 |
| Basic Average Shares | 14,095,371 | 12,566,500 | 12,240,542 | 12,197,615 |
| Diluted Average Shares | 14,095,371 | 12,623,412 | 12,240,542 | 12,197,615 |
Q32 Bio Inc. (QTTB)
Q32 Bio Inc. (QTTB)